Marcus M. Ilg

Chelmsford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Discovery of novel anti-fibrotics through phenotypic screening.

Discovery of novel anti-fibrotics through phenotypic screening.

Journal: Drug discovery today

Published: June 09, 2025

Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease.

Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease.

Journal: BJU international

Published: December 24, 2024

Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts.

Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts.

Journal: Frontiers in pharmacology

Published: November 11, 2024

TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation.

TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation.

Journal: Scientific reports

Published: January 17, 2024

Hydroxypyridone anti-fungals selectively induce myofibroblast apoptosis in an in vitro model of hypertrophic scars.

Hydroxypyridone anti-fungals selectively induce myofibroblast apoptosis in an in vitro model of hypertrophic scars.

Journal: European journal of pharmacology

Published: September 05, 2023

Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.

Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.

Journal: The journal of sexual medicine

Published: August 31, 2023

European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie's disease.

European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie's disease.

Journal: Sexual medicine

Published: April 12, 2023

A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals.

A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals.

Journal: The journal of sexual medicine

Published: March 21, 2023

Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.

Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.

Journal: The journal of sexual medicine

Published: December 12, 2022

Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars.

Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars.

Journal: European journal of pharmacology

Published: July 05, 2022

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.

Journal: PloS one

Published: February 19, 2022

Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.

Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.

Journal: The journal of sexual medicine

Published: April 22, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026